Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 26 July 2018

Indication(s)

Daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.

For HCV genotype specific activity, see sections 4.4 and 5.1.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/003768
Orphan designation No
Date First Approved 22-08-2014
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Bristol-Myers Squibb Pharma EEIG
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions